Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Obesity
1 other identifier
interventional
100
1 country
1
Brief Summary
The purpose of this study is to determine whether the probiotics will be effective in the treatment of obesity
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable obesity
Started Oct 2015
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 5, 2016
CompletedFirst Posted
Study publicly available on registry
April 11, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedMarch 10, 2017
March 1, 2017
2.2 years
April 5, 2016
March 9, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
change from baseline in fasting blood-glucose at 1 month
change of the fasting blood-glucose will be calculated at 1 month in comparison with the baseline
1 month
change from baseline in fasting blood-glucose at 3 months
change of the fasting blood-glucose will be calculated at 3 months in comparison with the baseline
3 months
change from baseline in glycosylated hemoglobin change at 1 month
change of the glycosylated hemoglobin will be calculated at 1 month in comparison with the baseline
1 month
change from baseline in glycosylated hemoglobin change at 3 months
change of the glycosylated hemoglobin will be calculated at 3 months in comparison with the baseline
3 months
Secondary Outcomes (38)
change from baseline in gut microbiota at 1 month
1 month
change from baseline in gut microbiota at 3 months
3 months
change from baseline in triglyceride at 1 month
1 month
change from baseline in triglyceride at 3 months
3 months
change from baseline in cholesterol at 1 month
1 month
- +33 more secondary outcomes
Study Arms (2)
Probiotics
EXPERIMENTALthe patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
Placebo
PLACEBO COMPARATORthe patients in this arm will receive placebo with similar appearance of probiotics.
Interventions
the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
Eligibility Criteria
You may qualify if:
- Age 15-60 years
- BMI≥28.0kg/m2
- Agree to cooperate in the trial
- Provision of written informed consent
You may not qualify if:
- With chronic gastrointestinal diseases, severe immune deficiency, lactose intolerance
- Diabetes
- Use antibiotics, bacteriostatic agents (eg berberine), lipid-lowering drugs, antacids, H2 Blockers, proton pump inhibitors, corticosteroids or sex hormones
- Use any probiotics in the last 3 months
- Allergic constitution
- Participating in any other clinical trials
- Was not able to insist until the end
- Pregnant and lactating women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai 10th People's Hospital
Shanghai, Shanghai Municipality, 200072, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Huanlong Qin
Shanghai 10th People's Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 5, 2016
First Posted
April 11, 2016
Study Start
October 1, 2015
Primary Completion
December 1, 2017
Study Completion
December 1, 2017
Last Updated
March 10, 2017
Record last verified: 2017-03